Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria: 1. Diagnosis of clinically possible, clinically probable laboratory-supported, clinically probable or clinically definite ALS (according to WNF EL Escorial diagnostic criteria, revised according to the Airlie House Conference 1998) 2. Onset of muscle weakness within 14 months randomization 3. Concomitant standard Riluzole therapy (50mg twice daily) Exclusion Criteria: 1. Presence of a tracheotomy, mechanical ventilation or non-invasive ventilation 2. Requirement for prescription drugs used for potential neuroprotective benefit -